Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease

被引：0

作者：

Otto J. Visser

Lars R. Perk

Josée M. Zijlstra

Guus A.M.S. van Dongen

Peter C. Huijgens

Arjan A. van de Loosdrecht

机构：

[1] VU University Medical Center,Department of Hematology

[2] VU University Medical Center,Department of Otolaryngology/Head and Neck Surgery

来源：

BioDrugs | 2006年 / 20卷

关键词：

Autologous Stem Cell Transplantation; Bone Marrow Involvement; Bone Marrow Infiltration; Tositumomab; Ibritumomab Tiuxetan;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Radioimmunotherapy (RIT) is a new treatment modality that combines the benefits of radiotherapy and immunotherapy. In RIT, a radionuclide is coupled to a monoclonal antibody, directed against an antigen expressed on tumor cells. Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL).

引用

页码：201 / 207

页数：6

共 50 条

[1] Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease
Visser, Otto J.
Perk, Lars R.
Zijlstra, Josee M.
van Dongen, Guus A. M. S.
Huijgens, Peter C.
van de Loosdrecht, Arjan A.
[J]. BIODRUGS, 2006, 20 (04) : 201 - 207
[2] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
Witzig, TE
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S91 - S95
[3] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
Thomas E. Witzig
[J]. Cancer Chemotherapy and Pharmacology, 2001, 48 : S91 - S95
[4] INOTUZUMAB OZOGAMICIN IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA REFRACTORY TO RITUXIMAB AND CHEMOTHERAPY OR RADIOIMMUNOTHERAPY
Goy, A.
Leach, J.
Tsai, M.
Foran, J.
Forero, A.
Wagner-Johnston, N.
Ehmann, C.
Egyed, M.
Ando, K.
Hatake, K.
Tobinai, K.
Feldman, T.
Vandendries, E.
Volkert, A.
Wang, S. L.
Ogura, M.
[J]. HAEMATOLOGICA, 2012, 97 : 324 - 324
[5] Radioimmunotherapy for B-cell non-Hodgkin lymphoma
Witzig, Thomas E.
[J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 655 - 668
[6] Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Graf, Solomon A.
Cassaday, Ryan D.
Morris, Karolyn K.
Behnia, Sanaz
Wu, Qian Vicky
Voutsinas, Jenna M.
Lynch, Ryan C.
Krakow, Elizabeth
Rasmussen, Heather A.
Chauncey, Thomas R.
Kanan, Sandra
Soma, Lorinda A.
Smith, Stephen D.
Gopal, Ajay K.
[J]. BLOOD, 2019, 134
[7] Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study
Graf, Solomon A.
Cassaday, Ryan D.
Morris, Karolyn K.
Rasmussen, Heather A.
Becker, Pamela S.
Chauncey, Thomas R.
Kanan, Sandra
Soma, Lorinda A.
Smith, Stephen D.
Gopal, Ajay K.
[J]. BLOOD, 2018, 132
[8] Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Ohmachi, Ken
Ando, Kiyoshi
Ogura, Michinori
Uchida, Toshiki
Itoh, Kuniaki
Kubota, Nobuko
Ishizawa, Kenichi
Yamamoto, Joji
Watanabe, Takashi
Uike, Naokuni
Choi, Ilseung
Terui, Yasuhito
Usuki, Kensuke
Nagai, Hirokazu
Uoshima, Nobuhiko
Tobinai, Kensei
[J]. CANCER SCIENCE, 2010, 101 (09) : 2059 - 2064
[9] Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
Rezvani, Andrew R.
Storer, Barry
Maris, Michael
Sorror, Mohamed L.
Agura, Edward
Maziarz, Richard T.
Wade, James C.
Chauncey, Thomas
Forman, Stephen J.
Lange, Thoralf
Shizuru, Judith
Langston, Amelia
Pulsipher, Michael A.
Sandmaier, Brenda M.
Storb, Rainer
Maloney, David G.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 211 - 217
[10] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
Postema, EJ
Boerman, OC
Oyen, WJG
Raemaekers, JMM
Corstens, FHM
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (11) : 1725 - 1735

← 1 2 3 4 5 →